Login / Signup

Authors' response to letter 'On the use of open-label studies for the evaluation of cannabis-based products for the treatment of long-COVID'.

Hannah ThurgurMichael LynskeyAnne Katrin SchlagCarol CroserDavid John NuttElizabeth Iveson
Published in: British journal of clinical pharmacology (2024)
Keyphrases
  • open label
  • coronavirus disease
  • sars cov
  • clinical trial
  • squamous cell carcinoma
  • phase ii
  • phase ii study
  • phase iii
  • case control
  • radiation therapy
  • locally advanced